285 related articles for article (PubMed ID: 12168109)
1. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
2. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
3. Cytoskeletons and antimitotic agents developed in Japan.
Nishio K; Saijo N
Anticancer Drug Des; 1999 Apr; 14(2):133-41. PubMed ID: 10405640
[TBL] [Abstract][Full Text] [Related]
4. Update on tubulin-binding agents.
Attard G; Greystoke A; Kaye S; De Bono J
Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
[TBL] [Abstract][Full Text] [Related]
5. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
6. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
7. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
8. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
Verrills NM; Kavallaris M
Curr Pharm Des; 2005; 11(13):1719-33. PubMed ID: 15892670
[TBL] [Abstract][Full Text] [Related]
9. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.
Jordan MA; Walker D; de Arruda M; Barlozzari T; Panda D
Biochemistry; 1998 Dec; 37(50):17571-8. PubMed ID: 9860873
[TBL] [Abstract][Full Text] [Related]
10. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
11. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
12. Interactions of antimitotic peptides and depsipeptides with tubulin.
Hamel E
Biopolymers; 2002; 66(3):142-60. PubMed ID: 12385035
[TBL] [Abstract][Full Text] [Related]
13. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
14. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
15. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin.
Wienecke A; Bacher G
Cancer Res; 2009 Jan; 69(1):171-7. PubMed ID: 19118000
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
17. Natural organic compounds that affect to microtubule functions.
Iwasaki S
Yakugaku Zasshi; 1998 Apr; 118(4):112-26. PubMed ID: 9564789
[TBL] [Abstract][Full Text] [Related]
18. Factors determining cellular mechanisms of resistance to antimitotic drugs.
Cabral F
Drug Resist Updat; 2001 Feb; 4(1):3-8. PubMed ID: 11512151
[TBL] [Abstract][Full Text] [Related]
19. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
Ayral-Kaloustian S; Zhang N; Beyer C
Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):443-7. PubMed ID: 19907719
[TBL] [Abstract][Full Text] [Related]
20. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
